



03-19-03

RCE # 1600

PTO/SB/30 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REQUEST  
FOR  
CONTINUED EXAMINATION (RCE)  
TRANSMITTAL**Address to:  
Commissioner for Patents  
Box RCE  
Washington, DC 20231

Application Number	09/519,188
Filing Date	March 6, 2000
First Named Inventor	Pancras C. Wong
Art Unit	1614
Examiner Name	Kim, Vickie Y.
Attorney Docket Number	PH 7038

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

## 1. Submission required under 37 CFR 1.114

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on \_\_\_\_\_  
(Any unentered amendment(s) referred to above will be entered).
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_
- iii. ☐ Other \_\_\_\_\_
- b. ☒ Enclosed
- i. ☐ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☒ Information Disclosure Statement (IDS)
- iv. ☐ Other \_\_\_\_\_

## 2. Miscellaneous

- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
- b. ☐ Other \_\_\_\_\_

## 3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 19-3880
- i. ☒ RCE fee required under 37 CFR 1.17(e) \$710.00
- ii. ☐ Extension of time fee (37 CFR 1.136 and 1.17) 03/21/2003 AHONDAF1 00000102 193880 09519188
- iii. ☐ Other 01 FC:1801 750.00 CH
- b. ☐ Check in the amount of \$ \_\_\_\_\_ enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Name (Print/Type)	Stephen B. Davis	Registration No. (Attorney/Agent)	26,693
Signature	<i>Stephen B. Davis</i>	Date	March 18, 2003

**CERTIFICATE OF MAILING OR TRANSMISSION**

Express Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type)	Eileen M. Immordino	Date	March 18, 2003
Signature	<i>Eileen M. Immordino</i>		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.



CASE PH 7038

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL825206395US  
Express Mail Label Number

March 18, 2003  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

PANCRAS C. WONG

APPLICATION NO: 09/519,188

FILED: MARCH 6, 2000

FOR: TREATMENT OF THROMBOSIS BY COMBINED USE OF A  
FACTOR XA INHIBITOR AND ASPIRIN

Assistant Commissioner for Patents  
Washington, D.C. 20231

#17  
RECEIVED  
MAR 21 2003  
TECH CENTER 1600/2000

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:


In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

These references were cited in a search report. Copies of these references and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-3791

  
Stephen B. Davis (26,693) on behalf of  
Jing S. Belfield, Ph.D.  
Agent for Applicant  
Reg. No. 45,914

Date: March 18, 2003